,49 Analysis of the residual malignant tumor cells revealed notably higher CD73 expression in the highly resistant subgroup and extensive TACSTD2 (TROP2) expression, which would also enlighten the study design of an ADC combination strategy as a perioperative setting for EGFR-mutant NSCLC.50 The gene discussed is TACSTD2; the disease is neoplasm.